Literature DB >> 26137210

P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use.

Nicholas B Norgard1, James J DiNicolantonio2.   

Abstract

Dual antiplatelet therapy (DAPT), which includes the combination of aspirin and a P2Y12 platelet receptor inhibitor, is a well-established antiplatelet regimen in the treatment of patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS). Three P2Y12 inhibitor options (clopidogrel, prasugrel and ticagrelor) are currently available, all having different efficacy and safety profiles along with contrasting contraindications, special warnings and precautions for use. This review compares and contrasts the unique P2Y12 antagonists in the NSTE-ACS setting, covering the latest evidence and their optimal use.

Entities:  

Keywords:  P2Y12 antagonists; acute coronary syndrome; clopidogrel; prasugrel; ticagrelor

Year:  2015        PMID： 26137210      PMCID： PMC4480548          DOI： 10.1177/2040622315584113

Source DB:  PubMed          Journal:  Ther Adv Chronic Dis        ISSN： 2040-6223            Impact factor:   5.091


  116 in total

1.  Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes.

Authors:  Gilles Montalescot; Leonardo Bolognese; Dariusz Dudek; Patrick Goldstein; Christian Hamm; Jean-Francois Tanguay; Jurrien M ten Berg; Debra L Miller; Timothy M Costigan; Jochen Goedicke; Johanne Silvain; Paolo Angioli; Jacek Legutko; Margit Niethammer; Zuzana Motovska; Joseph A Jakubowski; Guillaume Cayla; Luigi Oltrona Visconti; Eric Vicaut; Petr Widimsky
Journal:  N Engl J Med       Date:  2013-09-01       Impact factor: 91.245

2.  Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes.

Authors:  Christoph Varenhorst; Ulrica Alström; Oscar Ö Braun; Robert F Storey; Kenneth W Mahaffey; Maria Bertilsson; Christopher P Cannon; Benjamin M Scirica; Anders Himmelmann; Stefan K James; Lars Wallentin; Claes Held
Journal:  Heart       Date:  2014-06-23       Impact factor: 5.994

3.  Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.

Authors:  Thomas Cuisset; Corinne Frere; Jacques Quilici; Pierre-Emmanuel Morange; Lyassine Nait-Saidi; Joseph Carvajal; Agnès Lehmann; Marc Lambert; Jean-Louis Bonnet; Marie-Christine Alessi
Journal:  J Am Coll Cardiol       Date:  2006-09-12       Impact factor: 24.094

4.  Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.

Authors:  Kenneth W Mahaffey; Daniel M Wojdyla; Kevin Carroll; Richard C Becker; Robert F Storey; Dominick J Angiolillo; Claes Held; Christopher P Cannon; Stefan James; Karen S Pieper; Jay Horrow; Robert A Harrington; Lars Wallentin
Journal:  Circulation       Date:  2011-06-27       Impact factor: 29.690

Review 5.  Prevention and treatment of coronary distal embolization in the setting of acute myocardial infarction: pharmacologic approach.

Authors:  Alberto R De Caterina; Italo Porto; Giovanni Luigi De Maria; Adrian P Banning
Journal:  Curr Vasc Pharmacol       Date:  2012-07       Impact factor: 2.719

6.  Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.

Authors:  Paul A Gurbel; Kevin P Bliden; Kathleen Butler; Mark J Antonino; Cheryl Wei; Renli Teng; Lars Rasmussen; Robert F Storey; Tonny Nielsen; John W Eikelboom; Georges Sabe-Affaki; Steen Husted; Dean J Kereiakes; David Henderson; Dharmendra V Patel; Udaya S Tantry
Journal:  Circulation       Date:  2010-03-01       Impact factor: 29.690

7.  Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.

Authors:  Dimitrios Alexopoulos; Anastasia Galati; Ioanna Xanthopoulou; Eleni Mavronasiou; George Kassimis; Konstantinos C Theodoropoulos; George Makris; Anastasia Damelou; Grigorios Tsigkas; George Hahalis; Periklis Davlouros
Journal:  J Am Coll Cardiol       Date:  2012-07-17       Impact factor: 24.094

8.  Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.

Authors:  Matthew J Price; James S Walder; Brian A Baker; Darell E Heiselman; Joseph A Jakubowski; Douglas K Logan; Kenneth J Winters; Wei Li; Dominick J Angiolillo
Journal:  J Am Coll Cardiol       Date:  2012-06-19       Impact factor: 24.094

Review 9.  Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Authors:  Anne Bellemain-Appaix; Stephen A O'Connor; Johanne Silvain; Michel Cucherat; Farzin Beygui; Olivier Barthélémy; Jean-Philippe Collet; Laurent Jacq; François Bernasconi; Gilles Montalescot
Journal:  JAMA       Date:  2012-12-19       Impact factor: 56.272

Review 10.  Variability in responsiveness to oral antiplatelet therapy.

Authors:  Dominick J Angiolillo
Journal:  Am J Cardiol       Date:  2009-02-02       Impact factor: 2.778
View more
  1 in total

1.  Acquired Hemophilia A May Be Associated with Ticagrelor Therapy in a 52-Year-Old Man After a Recent Percutaneous Transluminal Coronary Angioplasty.

Authors:  Paola Pasquino; Roberto Canaparo; Tiziana Capello; Barbara Deorsola; Laura Perazzolo; Claudio Marengo; Loredana Serpe
Journal:  Clin Med Insights Case Rep       Date:  2016-09-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.